Clinical Status and Its Associated Early Warning Per Emerging Infectious Respiratory Disease in China
Tian Guizhen,Gao Zhancheng
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20141839
IF: 6.133
2014-01-01
Chinese Medical Journal
Abstract:In the past ten years, we had experienced a series of emerging severe acute respiratory infections (SARI). Some of them became serious public health emergent events, such as severe acute respiratory syndrome (SARS) and novel A/H7N9 avian influenza. Tracing back to 2003, SARS originated from Guangdong province and spread to 29 countries and regions until it was completely controlled. Out of 8 096 probable SARS cases world-wide, 774 patients died; the mortality was 9.6%.1 There were 5 327 patients with SARS in China, and 1 002 (19%) of them were health care workers (HCW). Nearly all the HCW got hospital acquired infection since there was no efficient preventive and protective system. However, ten years later, novel A/ H7N9 avian influenza, another emerging infectious disease, was identified in Shanghai City. In the more than two years, there have been a total of 435 cases with the novel A/H7N9 infection, and 166 patients died. The mortality is 38.2%.2 Even with such a serious situation, there are no hospital acquired infectious cases so far. Contrasting the scenario of these two severe emergent public health events in China, and overall aspects of public health, including early diagnosis, treatment, hospital infection control, epidemic spread control and public opinion and response, have shown great progress and a gratifying achievement. Besides SARS and A/H7N9 avian influenza, there are several other emerging or re-emerging respiratory diseases detected in our country that still require clinicians and Center for Disease Control and Prevention (CDC) staff at the frontline to pay attention to such events; such as A/ H5N1 avian influenza in 2005, EV71 inducing hand, foot, and mouth disease in 2008, A/H1N1 pandemic influenza in 2009, novel bunyavirus causing severe fever with thrombocytopenia syndrome in 2010, A/H10N8 avian influenza in 2013, and sporadic cases of plague every year. Meanwhile, we still need to keep an eye on some severe imported epidemic diseases, such as Middle East Respiratory Syndrome (MERS), and Ebola Hemorrhagic Fever. The occurrence of these diseases may not only seriously affect people's physical and mental health, but also have the potential to cause pandemics. Therefore, whether now or in the future, it is definitely important for us to have multiple comprehensive rational settings for early warning, diagnosis and treatment, infectious prevention, and control in community and tertiary hospitals for the reemerging and emerging respiratory diseases. We have to be concerned about the following aspects. Traceability of the case with emerging or reemerging infection So far, there are two types of the emerging and re-emerging diseases, human-derived and zoonotic diseases. In recent years, at least two kinds of human-derived respiratory infectious disease outbreak were identified in the mainland of China. One is EV71 virus resulting in the outbreak of hand, foot, and mouth disease and causing fatal neurogenic pulmonary edema, which might be imported from other countries or regions.3 The other disease is 2009 A/H1N1 influenza pandemic that originated in Mexico and led to an influenza infection widely spreading among the global population.4 The acute respiratory infectious zoonosis with human transmission can originate in poultry (A/H5N1, A/H7N9 and A/H10N8 influenza virus), be vector borne (novel bunyavirus) or contracted from the masked civet or bats (SARS coronavirus). The interspecies transmission routes of these viruses to humans have tremendously threatened and greatly impacted public health and social stability. For this reason, the best way to manage the epidemic situation is to isolate both human cases with infection and associated creatures carrying pathogens in order to cut off the transmission route and effectively prevent further spreading. Nonetheless, anyone with close exposure to any patient with respiratory infectious disease without personal protective equipment (PPE) will get infected to varying degrees, which will result in limited human to human transmission, such as severe cases with human granulocytic anaplasmosis and novel bunyavirus infection.5,6 Pathogen diagnosis in the majority of hospitals in our country is still limited at the stage of bacterial culture, in which it is hard to differentiate infections with viral or atypical pathogens. This then will cause a dilemma for identifying the real pathogen in time. Currently, the early warning for re-emerging or emerging infectious diseases is largely dependent on both clinicians' awareness to clusters of cases and hospital acquired infection, and the collaborative work of multiple disciplines, especially between clinicians and CDC staff. Clinical status in quo per the merging and re-emerging infectious diseases in China Diversity of pathogens causes emerging respiratory infection with potential for transmission and spreading. Regardless if they are emerging or re-emerging SARI, pathogens are nothing more than virus, mycoplasma, rickettsia, or bacteria, but the infectious diseases driven by RNA or DNA viruses make up a major proportion of the pathogens. Examples include type 55 adenovirus, herpes virus, Bocavirus, influenza virus (especially avian A/H7N9, A/H5N1), rhinovirus, SARS coronavirus, and MERS coronavirus. We have to be aware of and clarify that all the pathogens could result in 'effective' (like influenza virus and SARS coronavirus) or 'limited' (like A/H7N9, adenovirus 55 and human granulocytic anaplasmosis) human to human transmission in certain environments. So far, it is difficult to identify the emerging SARI at an early stage since it has a complicated manifestations. The clinical presentation of different pathogens often show a similar scenario with mild, moderate, severe and critically severe clinical status in quo without specific traits; especially for viral infections. The infectious infiltration can be involved in one or multiple lobes of either unilateral or bilateral lungs. The development of infiltrations in some cases progresses rapidly and shows diffused consolidation in bilateral lungs in a short period if not ameliorated in time. The patient will then deteriorate to acute respiratory distress syndrome (ARDS) with complications including multiple organ dysfunction or failure, such as heart, liver and kidney. It is the nonspecific clinical manifestations after pathogen infection that greatly increases the difficulty of clinical surveillance and differential diagnosis, and delays recognizing the cycle of the disease. As mentioned above, bacterial culture is only a small part of the diagnostic tools for emerging SARI surveillance. It barely meets the demand of urgent response for real clinical practice. Exploration and wide application of molecular diagnostic tools will have many promising advantages for the timely detection and identification of emerging SARI. Devoid of efficient and optimized therapeutic strategies for the severe and critically severe SARI patients The human population is generally susceptibility to the emerging SARI pathogen since humans lack a specific immune response to novel pathogens. There is also no targeted therapy and no effective and specific anti-infection reagents. All the current therapeutic strategies are mainly focused on symptomatic administration and supportive treatment, except for the early use of neuraminidase inhibitors for treating influenza virus infections. For treating patients with ARDS, the pivotal strategies basically focus on how to guarantee rational oxygenation by invasive or noninvasive mechanical ventilation. There are other treatments, including prone position ventilation, high frequency ventilation, and extra-corporeal membrane oxygenation, that are being prepared to enter the therapeutic field for treating the disease properly. Corticosteroids are not routinely recommended, especially in early and late ARDS stages. If corticosteroids need to be administrated after prudent evaluation, lower dosages and short-term administration of this 'double bladed' reagent should be used. That is, the equivalent of methylprednisolone less than 2 mg/kg for about 1 week.7–11 For viral induced SARI, the specific neutralizing antibody may exist in the convalescent patient's plasma at a high titter, and has the capacity for tremendously reducing the viral load and viral shedding. Thus, critically severe patients infected with the same virus could quickly recover if they are treated with convalescent or vaccinated plasma.12 Therefore, it is most important for clinicians to have the capability and capacity to differentiate and recognize early warning signs of the emerging or re-emerging SARI, such as SARS, MERS and avian influenza. Tertiary hospitals in China, at least, should be provided with rapid and specific molecular diagnostic kits for multiple pathogens for exclusion of the frequently seen pathogens in order to have an early warning for the detection of novel pathogen infections. Consequently, the mortality of critical severe SARI patients could be tremendously decreased. For hospital infection control, the government should help to build up a series of well-prepared protective settings such as negative pressure intensive care unit rooms and associated instruments in the intensive care unit. Finally, teamwork involving multiple discipline expertise should be further intensified in the future for both pathogen detection and patient treatment.